Breaks Categories: News

TuesdayFeb 17, 2026 9:26 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs Exclusive Costa Rica Distribution Deal for AVERSA Fentanyl and Sports Tape Products 

Nutriband (NASDAQ: NTRB) announced it has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA Fentanyl, upon approval, and all sports tape products manufactured at its Pocono Pharmaceutical/Active Intell subsidiary. Under the agreement, Innomedica will oversee and finance regulatory approvals as the products advance toward launch. Nutriband’s AVERSA abuse-deterrent transdermal technology is designed to incorporate aversive agents into patches to deter abuse, diversion and misuse of drugs with abuse potential, supported by a broad international patent portfolio.  To view the full press release, visit https://ibn.fm/2YOl8  About Nutriband Inc.  We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch…

Continue Reading

TuesdayFeb 17, 2026 9:00 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands European Clinical Network to Support GelrinC(R) Commercial Strategy

Regentis Biomaterials (NYSE American: RGNT) announced the expansion of its European clinical site network into new markets, including Italy and Eastern Europe, to support ongoing clinical programs and the commercial strategy for GelrinC(R), which has received CE Mark approval for knee cartilage repair. The expanded network includes leading academic and regional medical centers across Italy, Germany, Serbia, Slovenia and Romania, strengthening the company’s engagement with orthopedic surgeons and centers of excellence as it advances broader clinical adoption and evaluates commercial partnership opportunities in Europe. To view the full press release, visit https://ibn.fm/ala7S About Regentis Biomaterials Regentis Biomaterials Ltd is a…

Continue Reading

ThursdayFeb 12, 2026 10:50 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options

Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated 2026 milestones across its late-stage rare disease pipeline, including top-line data from the Phase 3 FLASH2 trial of HyBryte™ in early-stage cutaneous T-cell lymphoma expected in the second half of 2026, with an interim analysis approaching in the second quarter and 66 of 80 patients enrolled as of Feb. 10. The letter also reviewed positive Phase 2a data for SGX945 (dusquetide) in Behçet’s Disease published in Rheumatology (Oxford), encouraging Phase 2a psoriasis results for SGX302, ongoing strategic evaluations including partnership and M&A opportunities, and the company’s…

Continue Reading

ThursdayFeb 12, 2026 10:39 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery 

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Bioscience announced key advancements in their global intellectual property portfolio supporting OT-101, a proprietary TGF-β antisense therapeutic platform, with allowed patent claims in Australia covering OT-101 (SEQ ID NO:9) for the treatment of Parkinson’s Disease, including associated sleep-related symptoms, and granted utility model patents in China and Germany for an intracranial continuous infusion delivery device. The company stated the expanded protection spans therapeutic use claims, CNS delivery methods, device-enabled administration and broader oncology and neurology applications, forming an integrated commercialization platform intended to strengthen long-term defensibility, support strategic partnerships and enhance shareholder value, with additional data presentations planned…

Continue Reading

ThursdayFeb 12, 2026 9:20 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox

NanoViricides, Inc. (NYSE American: NNVC) announced it has filed an application for Orphan Drug Designation for NV-387 as a treatment for MPox with the U.S. FDA Office of Orphan Products Development. If granted, the designation would provide incentives including tax credits for qualified clinical trials, exemption from certain user fees and potential seven years of market exclusivity following approval. The company highlighted ongoing global MPox concerns, limited therapeutic options and challenges associated with existing smallpox antivirals such as TPOXX(R) and TEMBEXA(R), noting continued viral mutations and the need for an effective therapeutic solution. To view the full press release, visit…

Continue Reading

TuesdayFeb 10, 2026 9:00 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) to Report Fourth-Quarter 2025 Financial Results Feb. 17

Earth Science Tech (OTC: ETST), a strategic holding company focused on acquiring and scaling high-potential operating businesses, announced that it will report financial results for the three months ended Dec. 31, 2025, after the close of trading on Tuesday, Feb. 17, 2026. To view the full press release, visit https://ibn.fm/FnUf9 About Earth Science Tech, Inc. (ETST) Earth Science Tech, Inc. is a diversified holding company focused on the health and wellness sector. Through its wholly-owned subsidiaries, ETST operates a vertically integrated portfolio that includes high-quality compounding pharmacies, telemedicine platforms, and targeted healthcare facilities. The Company currently owns RxCompoundStore.com and Mister…

Continue Reading

MondayFeb 09, 2026 9:10 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics using proprietary intranasal delivery technology, today outlined targeted milestones for 2026 as it advances ONP-002, a novel intranasal neurosteroid, toward Phase 2 clinical development. The Company is preparing to initiate a Phase 2a clinical trial of ONP-002 in Australia for the treatment of concussion and mild traumatic brain injury (mTBI), positioning the candidate as a potential first-in-class pharmacological therapy for a large and underserved global market following positive preclinical and Phase 1 safety and efficacy results. To view the full press release, visit https://ibn.fm/s5NeN About Oragenics, Inc. Oragenics, Inc.…

Continue Reading

ThursdayFeb 05, 2026 9:20 am

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer

TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug ("IND") application amendment to the U.S. Food and Drug Administration for a planned Phase 2a clinical trial of its lead candidate, TTX-MC138, to be conducted by Quantum Leap Healthcare Collaborative within the PRE-I-SPY program. The dose-expansion study is expected to enroll up to 45 colorectal cancer patients who have completed standard curative-intent therapy and test positive for circulating tumor DNA ("ctDNA"), a marker associated with minimal residual disease ("MRD") and cancer recurrence, with the trial planned to begin in the first half of 2026 under the leadership of…

Continue Reading

ThursdayFeb 05, 2026 9:10 am

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn

Telomir Pharmaceuticals (NASDAQ: TELO) announced new cellular study results showing that Telomir-1, administered as Telomir-Zn, induces a rapid and coordinated redistribution of intracellular metals, simultaneously increasing zinc levels while reducing redox-active ferrous iron in living cells. The company said the findings extend its previously reported iron-reduction data by demonstrating, for the first time, a coupled intracellular metal-modulating mechanism rather than simple extracellular chelation, supporting a potential upstream approach to addressing oxidative stress, mitochondrial dysfunction, epigenetic instability, and genomic damage associated with cancer and aging. To view the full press release, visit https://ibn.fm/MPLBG About Telomir Pharmaceuticals Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is…

Continue Reading

WednesdayFeb 04, 2026 9:00 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Appoints Ori Gon as CFO and Chief Business Officer

Regentis Biomaterials (NYSE American: RGNT) announced the appointment of Ori Gon as chief financial officer and chief business officer, effective immediately. Gon will oversee the company’s commercial and business development initiatives, as well as financial strategy, planning and reporting, as Regentis advances GelrinC(R) toward commercialization in Europe following CE Mark approval and continues its pivotal Phase III FDA clinical trial in the United States. To view the full press release, visit https://ibn.fm/E8WA4 About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an…

Continue Reading